What is Psychemedics Corporation?
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally.
PMDI · Verdict
Moderate reward · moderate risk
PMDI's standout is volatility, while profitability remains the main concern.
Based on 88% data coverage
PMDI · Verdict
Top decile vs peers
-9% net margin · -32% ROE
Model-based scoring. For information only — not financial advice.
Psychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising aka K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 10.08M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.